Dihexa
Prescription OnlyOverview
Dihexa is a cognitive enhancement peptide and angiotensin IV analog studied for its potent neurotrophic effects. It has limited clinical data and is on the FDA's radar for Category 1 placement. A small but dedicated user base exists in Australia with growing grey market demand.
Australian Scheduling
Schedule 4 (Prescription Only). Under monitoring due to limited clinical evidence and growing unregulated demand. FDA Category 1 list placement expected.
Access Pathway
Limited prescription availability with 3 identified providers. Some supply through research chemical channels.
For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.